(Q73734635)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

A W Partin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

L S Marks

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 April 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

4 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

132-136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

Precipitating antigens of the normal human prostate.

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

The use of percent free prostate specific antigen for staging clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900958-4

7 January 2021

10.1016/S0090-4295(00)00958-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11295611%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference